Evidence map›Paper›PMID 39174722›Full record

ArticleScientific reports2024

Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.

Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Bangkok declarations on cancer control in Asia.The Lancet regional health. Western Pacific · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pojsakorn Danpanichkul *Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Kanokphong Suparan *Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Banthoon SukphutananFaculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Chuthathip KaeosriFaculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Primrose TothanarungrojFaculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Supapitch SirimangklanurakFaculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Markos KalligerosDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Natchaya PolpichaiDepartment of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, USA.
Yanfang PangAffiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Karn WijarnpreechaDivision of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
Pimsiri SripongpunGastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Naichaya ChamroonkulGastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Mindie H NguyenDepartment of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Teerha PiratvisuthNKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand.
Apichat KaewdechGastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. Apichat.ka@psu.ac.th.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary liver cancer is the third leading cause of cancer-related mortality. The increasing prevalence of metabolic syndrome and alcohol consumption, along with the existing burden of viral hepatitis, could significantly heighten the impact of primary liver cancer. However, the specific effects of these factors in the Asia-Pacific region, which comprises more than half of the global population, remain largely unexplored. This study aims to analyze the epidemiology of primary liver cancer in the Asia-Pacific region. We evaluated regional and national data from the Global Burden of Disease study spanning 2010 to 2019 to assess the age-standardized incidence, mortality, and disability-adjusted life years associated with primary liver cancer in the Asia-Pacific region. During the study period, there were an estimated 364,700 new cases of primary liver cancer and 324,100 deaths, accounting for 68 and 67% of the global totals, respectively. Upward trends were observed in the age-standardized incidence rates of primary liver cancer due to metabolic dysfunction-associated fatty liver disease (MASLD) and alcohol-associated liver disease (ALD) in the Asia-Pacific region, as well as an increase in primary liver cancer from Hepatitis B virus infection in the Western Pacific region. Notably, approximately 17% of new cases occurred in individuals aged 15-49 years. Despite an overall decline in the burden of primary liver cancer in the Asia-Pacific region over the past decade, increases in incidence were noted for several etiologies, including MASLD and ALD. However, viral hepatitis remains the leading cause, responsible for over 60% of the total burden. These findings underscore the urgent need for comprehensive strategies to address the rising burden of primary liver cancer in the Asia-Pacific region.

Indexed as

Liver NeoplasmsAdolescentAdultAgedAsiaDisability-Adjusted Life YearsFemaleGlobal Burden of DiseaseHumansIncidenceMaleMiddle AgedPrevalenceYoung AdultAlcohol-associated liver diseaseAsia–PacificEpidemiologyLiver cancerMetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID39174722
PMCPMC11341810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.